Cite
The PROSIT-BIO Cohort: A Prospective Observational Study of Patients with Inflammatory Bowel Disease Treated with Infliximab Biosimilar.
MLA
Fiorino, Gionata, et al. “The PROSIT-BIO Cohort: A Prospective Observational Study of Patients with Inflammatory Bowel Disease Treated with Infliximab Biosimilar.” Inflammatory Bowel Diseases, vol. 23, no. 2, Feb. 2017, pp. 233–43. EBSCOhost, https://doi.org/10.1097/MIB.0000000000000995.
APA
Fiorino, G., Manetti, N., Armuzzi, A., Orlando, A., Variola, A., Bonovas, S., Bossa, F., Maconi, G., D’Incà, R., Lionetti, P., Cantoro, L., Fries, W., Annunziata, M. L., Costa, F., Terpin, M. M., Biancone, L., Cortelezzi, C. C., Amato, A., Ardizzone, S., & Danese, S. (2017). The PROSIT-BIO Cohort: A Prospective Observational Study of Patients with Inflammatory Bowel Disease Treated with Infliximab Biosimilar. Inflammatory Bowel Diseases, 23(2), 233–243. https://doi.org/10.1097/MIB.0000000000000995
Chicago
Fiorino, Gionata, Natalia Manetti, Alessandro Armuzzi, Ambrogio Orlando, Angela Variola, Stefanos Bonovas, Fabrizio Bossa, et al. 2017. “The PROSIT-BIO Cohort: A Prospective Observational Study of Patients with Inflammatory Bowel Disease Treated with Infliximab Biosimilar.” Inflammatory Bowel Diseases 23 (2): 233–43. doi:10.1097/MIB.0000000000000995.